Sequencing Therapy for Genetically Defined Subgroups of Non-Small Cell Lung Cancer. Review uri icon

Overview

abstract

  • The practice of precision medicine for patients with metastatic non-small cell lung cancer (NSCLC), particularly those patients with adenocarcinoma histology (the predominant subtype of NSCLC), has become the accepted standard of care worldwide. Implementation of prospective tumor molecular profiling and rational therapeutic decision-making based on the presence of recurrently detected oncogenic "driver" alterations in the tumor genome has revolutionized the way that lung cancer is diagnosed and treated in the clinic. Over the past two decades, there has been a deluge of therapeutically actionable driver alterations and accompanying small molecule inhibitors to target these drivers. Herein, we synthesize a large and rapidly growing body of literature regarding therapeutic inhibition of driver mutations. We focus on established targets, including EGFR, anaplastic lymphoma kinase (ALK), ROS1, BRAF, RET, MET, HER2, and neurotrophic tyrosine kinase receptor (NTRK), with a particular emphasis on the sequencing of small molecule inhibitors in these genetically defined cohorts of patients with lung cancer.

publication date

  • May 23, 2018

Research

keywords

  • Carcinoma, Non-Small-Cell Lung
  • Lung Neoplasms

Identity

PubMed Central ID

  • PMC10172876

Scopus Document Identifier

  • 85056039559

Digital Object Identifier (DOI)

  • 10.1200/EDBK_201331

PubMed ID

  • 30231382

Additional Document Info

volume

  • 38